Table 4 Correlation between LAG-3 expression and prognosis in various malignancies
Article | Type of cancer | Classification | Case | Method | Prognosis |
|---|---|---|---|---|---|
Zaitsu S. (present study) | Ovarian cancer | Clear cell carcinoma | 171 | IHC | poor OS and PFS |
Victor S. (2021) | Breast cancer | Variety (after neoadjuvant therapy) | 66 | IHC | No significant difference |
Maximilian J. M. (2021) | Glioma | Variety | 97 | IHC | No significant difference |
Artem G. (2021) | Classic Hodgkin lymphoma | Hodgkin lymphoma | 15 | IHC | No significant difference |
Chubin L. (2021) | Liver cancer | Sarcomatoid HCC | 31 | IHC | No significant difference |
Kristiina K. (2021) | Classic Hodgkin lymphoma | Hodgkin lymphoma | 131 | IHC | No significant difference |
Lena S. (2021) | Pancreatic cancer | Pancreatic ductal carcinoma | 69 | multiplex IF | poor DFS |
John A. (2021) | Osteosarcoma | Pulmonary metastasis | 25 | IHC | poor PFS |
Luo F. (2021) | Nasopharyngeal carcinoma | Variety | 182 | IHC | poor DFS |
Gaëlle Rhyner Agocs (2021) | Colon cancer | Stage II | 142 | IHC | favorable DFS |
Takeuchi M. (2020) | Adult T cell leukemia/lymphoma | Variety | 69 | IHC | No significant difference |
Mengzhou G. (2020) | Liver cancer | HCC | 143 | IF | poor OS and DFS |
Gebauer F. (2020) | Esophageal cancer | Adenocarcinoma | 421 | IHC, IF | favorable OS |
Xiao S. (2020) | Thyroid cancer | Medullary thyroid cancer | 200 | IHC | No significant difference |
Félix B. (2020) | Ovarian cancer | Variety | 98 | IHC | No significant difference |
Ila D. (2019) | Lung cancer | Variety (after ICI treatment via PD-1) | 90 | multiplexed QIF | poor PFS |
Christoph M. (2019) | Nasopharyngeal carcinoma | Variety | 30 | IHC | No significant difference |
Wenjia W. (2019) | Esophageal cancer | SCC | 261 | IHC | poor OS and RFS |
Hong W. (2019) | Oral carcinoma | SCC (before nimotuzumab therapy) | 36 | IHC | poor OS |
Fucikova J. (2019) | Ovarian cancer | HGSC | 80 | IHC | favorable RFS and OS |
Jingjing D. (2018) | Esophageal | SCC (after esophagectomy) | 55 | IHC | No significant difference |
Sigurd M. (2017) | Lung cancer | Variety | 500 | IHC | favorable DSS |
Burugu S. (2017) | Breast cancer | Variety | 3992 | IHC | favorable CSS |
Yayi H. (2017) | Lung cancer | Variety | 139 | IHC | poor OS and PFS |
Wei-Wei D. (2016) | Head and neck cancer | SCC | 194 | IHC, IF | poor OS (negative LN metastasis) |
Giulia B. (2016) | Breast cancer | Triple-negative (after adjuvant chemotherapy) | 104 | IHC | poor OS and RFS |